Dry Powder Inhaler Devices Pipeline Product Market Landscape Report 2021 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Dry Powder Inhaler Devices - Medical Devices Pipeline Product Landscape, 2021" report has been added to ResearchAndMarkets.com's offering.

"Dry Powder Inhaler Devices - Medical Devices Pipeline Product Landscape, 2021" provides comprehensive information about the Dry Powder Inhaler Devices pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Dry powder inhaler devices deliver medication to the lungs in the form of a dry powder.

Scope

• Extensive coverage of the Dry Powder Inhaler Devices under development
• The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
• The report reviews the major players involved in the development of Dry Powder Inhaler Devices and list all their pipeline projects
• The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
• The report provides key clinical trial data of ongoing trials specific to pipeline products
• Recent developments in the segment / industry

Key Topics Covered:

1 Tables & Figures

2 Introduction

2.1 Dry Powder Inhaler Devices Overview

3 Products under Development

3.1 Dry Powder Inhaler Devices - Pipeline Products by Stage of Development

3.2 Dry Powder Inhaler Devices - Pipeline Products by Territory

3.3 Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path

3.4 Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date

3.5 Dry Powder Inhaler Devices - Ongoing Clinical Trials

4 Dry Powder Inhaler Devices - Pipeline Products under Development by Companies

4.1 Dry Powder Inhaler Devices Companies - Pipeline Products by Stage of Development

4.2 Dry Powder Inhaler Devices - Pipeline Products by Stage of Development

5 Dry Powder Inhaler Devices Companies and Product Overview

5.1 Adamis Pharmaceuticals Corp

5.2 Advent Pharmaceuticals Pty Ltd

5.3 Aespira Ltd.

5.4 AKELA Pharma Inc. (Inactive)

5.5 AstraZeneca Plc

5.6 Bayer AG

5.7 Cambridge Healthcare Innovations Ltd

5.8 Circassia Group Plc

5.9 Creare LLC

5.10 Eli Lilly and Co

5.11 GlaxoSmithKline Plc

5.12 Glenmark Pharmaceuticals Ltd

5.13 Hovione Technology Ltd

5.14 Iconovo AB

5.15 Liquidia Technologies Inc

5.16 Lupin Pharmaceuticals Inc

5.17 MannKind Corp

5.18 Monash University

5.19 Nektar Therapeutics

5.20 Ology Bioservices Inc

5.21 OPKO Health Inc

5.22 OtiTopic Inc

5.23 Pharmaxis Ltd

5.24 Quench Medical Inc

5.25 Respira Therapeutics Inc

5.26 Respirent Pharmaceuticals Co Ltd

5.27 Sandoz International GmbH

5.28 Sheffield Hallam University

5.29 Shin Nippon Biomedical Laboratories Ltd

5.30 Spyryx Biosciences Inc

5.31 Sun Pharma Advanced Research Company Ltd

5.32 United Therapeutics Corp

5.33 University of Kansas

5.34 University of Sydney

5.35 University of Texas Medical Branch at Galveston

5.36 Vectura Group Plc

5.37 Verona Pharma Plc

5.38 Virginia Commonwealth University

6 Dry Powder Inhaler Devices- Recent Developments

6.1 Jun 08, 2021: MannKind at the Lytham Partners Summer 2021 Investor Conference

6.2 May 06, 2021: Nektar Therapeutics Reports First Quarter 2021 Financial Results

6.3 Apr 28, 2021: Teva Reports First Quarter 2021 Financial Results

6.4 Apr 27, 2021: Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed

6.5 Apr 12, 2021: Orion publishes Interim Report for January-March 2021 on Tuesday 27 April 2021

6.6 Apr 06, 2021: GSK announces Dr Anne Beal to join the Board as Non-Executive Director

6.7 Mar 29, 2021: Chiesi and Hephai join forces to develop AI educational tool to improve inhaler use

6.8 Mar 25, 2021: Decisions taken by Orion Annual General Meeting on 25 March 2021

6.9 Mar 22, 2021: Novartis appoints Karen Hale as Chief Legal Officer

6.10 Mar 19, 2021: GSK to highlight scientific research in ovarian and endometrial cancer at SGO 2021 Annual Meeting on Women's Cancer

6.11 Mar 10, 2021: MannKind Corporation to Participate in Oppenheimer's 31st Annual Healthcare Conference

6.12 Mar 03, 2021: Change to the Notice of Orion Annual General Meeting

6.13 Mar 02, 2021: MannKind to Participate in H.C. Wainwright Global Life Sciences Conference

6.14 Mar 01, 2021: Teva to Present at the J.P. Morgan 2021 Global High Yield and Leveraged Finance Conference

6.15 Feb 18, 2021: MannKind to Hold 2020 Fourth Quarter and Full Year Financial Results Conference Call on February 25, 2021

6.16 Feb 18, 2021: OPKO Health Reports 2020 Fourth Quarter Business Highlights and Financial Results

6.17 Feb 18, 2021: Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2020 on Thursday, February 25, 2021

6.18 Feb 18, 2021: MannKind Corporation to Participate in 2021 SVB Leerink Global Healthcare Conference

6.19 Feb 18, 2021: Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2020 on Thursday, February 25, 2021, After Close of U.S.-Based Financial Markets

6.20 Feb 11, 2021: Acknowledged scientific leader and Novartis veteran joins Sai Life Sciences

6.21 Feb 08, 2021: GSK Consumer Health Pakistan appoints Farhan Muhammad Haroon as CEO

6.22 Feb 02, 2021: Jim Fitterling elected to 3M board of directors

6.23 Jan 26, 2021: Adamis Pharmaceuticals provides update on its us compounding business

6.24 Jan 12, 2021: Vectura Group: Trading update

6.25 Jan 06, 2021: Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference

6.26 Jan 04, 2021: MannKind to Participate in H.C. Wainwright Bioconnect 2021 Conference

6.27 Nov 26, 2020: GLAXOSMITHKLINE: EMTN supplementary prospectus

6.28 Oct 23, 2020: Orion starts biologic joint venture in China

6.29 Sep 01, 2020: Novartis announces ambitious ESG targets to increase access to medicines and achieve full carbon neutrality

6.30 Jul 10, 2020: Operation Clean Sweep

6.31 Jul 09, 2020: Teva to Host Conference Call to Discuss Second Quarter 2020 Financial Results at 8 a.m. ET on August 5, 2020

7 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/ok5gev

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900